Related references
Note: Only part of the references are listed.Body Composition, Symptoms, and Survival in Advanced Cancer Patients Referred to a Phase I Service
Henrique A. Parsons et al.
PLOS ONE (2012)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Does Obesity Influence the Prognosis of Metastatic Renal Cell Carcinoma in Patients Treated with Vascular Endothelial Growth Factor-Targeted Therapy?
Sandra Steffens et al.
ONCOLOGIST (2011)
Visceral Fat Area as a New Independent Predictive Factor of Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Antiangiogenic Agents
Sylvain Ladoire et al.
ONCOLOGIST (2011)
Impact of Body Composition on Clinical Outcomes in Metastatic Renal Cell Cancer
Patricia A. Tang et al.
ONCOLOGIST (2011)
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma
S. Antoun et al.
ANNALS OF ONCOLOGY (2010)
Anabolic and catabolic pathways regulating skeletal muscle mass
John J. McCarthy et al.
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE (2010)
Cancer cachexia
Michael J. Tisdale
CURRENT OPINION IN GASTROENTEROLOGY (2010)
Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
Vanessa P. Houde et al.
DIABETES (2010)
Association of Skeletal Muscle Wasting With Treatment With Sorafenib in Patients With Advanced Renal Cell Carcinoma: Results From a Placebo-Controlled Study
Sami Antoun et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer
Benjamin H. L. Tan et al.
CLINICAL CANCER RESEARCH (2009)
Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment
Carla M. M. Prado et al.
CLINICAL CANCER RESEARCH (2009)
An Emerging Role of mTOR in Lipid Biosynthesis
Mathieu Laplante et al.
CURRENT BIOLOGY (2009)
Dietary factors and cancer chemoprevention: An overview of obesity-related malignancies
N. S. Murthy et al.
JOURNAL OF POSTGRADUATE MEDICINE (2009)
A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care
Marina Mourtzakis et al.
APPLIED PHYSIOLOGY NUTRITION AND METABOLISM (2008)
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
Naeem Bhojani et al.
EUROPEAN UROLOGY (2008)
Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study
Carla M. M. Prado et al.
LANCET ONCOLOGY (2008)
Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity
Carla M. M. Prado et al.
CLINICAL CANCER RESEARCH (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image
W Shen et al.
JOURNAL OF APPLIED PHYSIOLOGY (2004)
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
A Trotti et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo
SC Bodine et al.
NATURE CELL BIOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
